糖尿病对食管癌多模式治疗病理缓解的影响
基于胸外科医师学会普胸外科数据库2012至2019年9171例接受新辅助治疗后食管切除术的患者,比较糖尿病与非糖尿病患者的病理完全缓解(pCR,定义为ypT0 N0)。单因素分析显示糖尿病患者pCR率较低(16% vs 18%,P=0.026),但多因素分析中糖尿病并非pCR的独立相关因素(OR 0.89,95%CI 0.78-1.01,P=0.075)。作者认为糖尿病患者在新辅助治疗后达到pCR的可能性可能较低,提示需进一步探索。
要点
- 9171例中糖尿病患者2011例(22%),非糖尿病7160例(78%)。
- 单因素分析糖尿病患者pCR率16% vs 非糖尿病18%(P=0.026)。
- 多因素分析糖尿病与pCR无独立关联(OR 0.89,95%CI 0.78-1.01,P=0.075)。
核心结论
- 糖尿病患者在新辅助治疗食管癌后达到pCR的可能性可能低于非糖尿病患者。
- 作者认为这提示需进一步探索,因为糖尿病食管癌患者可能从与非糖尿病者不同的治疗模式中获益。
研究设计与样本
- 回顾性研究,使用胸外科医师学会普胸外科数据库,纳入2012年至2019年间接受新辅助治疗后食管切除术的所有食管癌患者。
- 共9171例符合纳入标准,按有无糖尿病分组比较,pCR定义为ypT0 N0。
主要发现
- 9171例中糖尿病患者2011例(22%),非糖尿病患者7160例(78%)。
- 糖尿病患者年龄更大、更可能为男性、更可能合并所有合并症。
- 单因素分析显示糖尿病患者pCR率较低(16% vs 18%,P=0.026)。
- 多因素分析显示糖尿病患者达到pCR的优势有降低趋势,但糖尿病并非pCR的独立相关因素(OR 0.89,95%CI 0.78-1.01,P=0.075)。
关键数值与推荐
- pCR定义为ypT0 N0。
- 单因素分析糖尿病患者pCR率16% vs 非糖尿病18%(P=0.026)。
- 多因素分析糖尿病与pCR的OR 0.89(95%CI 0.78-1.01,P=0.075)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The incidence of esophageal cancer has increased faster than that of most cancers. Evidence from other malignant neoplasms suggests that diabetic patients have a worse response to multimodality therapy. We hypothesized that diabetic patients with esophageal cancer will have a decreased response to neoadjuvant chemotherapy and radiation therapy compared with nondiabetic patients. METHODS: A retrospective study of The Society of Thoracic Surgeons General Thoracic Surgery Database identified all patients who had an esophagectomy after neoadjuvant therapy for esophageal cancer between 2012 and 2019. Patients were compared on the basis of the presence of diabetes. A pathologic complete response (pCR) was defined as ypT0 N0. The χ2 and Wilcoxon rank sum tests were used to compare patients' demographic and clinical characteristics between those with and those without diabetes. Multivariable logistic regression was used to evaluate the predictors of response to neoadjuvant therapy. RESULTS: Of the 9171 patients who met inclusion criteria, 2011 (22%) patients were diabetic and 7160 (78%) patients were nondiabetic. Patients with diabetes were older, more likely to be male, and more likely to have all comorbidities. Univariate analysis revealed that diabetic patients were less likely to have pCR (16% vs 18%; P = .026). Although multivariable analysis showed a trend toward diabetic patients' having lower odds of achieving pCR, diabetes was not independently associated with pCR (odds ratio, 0.89; 95% CI, 0.78-1.01; P = .075). CONCLUSIONS: Diabetic patients may be less likely than nondiabetic patients to achieve pCR after neoadjuvant treatment of esophageal cancer. This suggests the need for further exploration as diabetic patients with esophageal cancer can potentially benefit from different treatment paradigms compared with their nondiabetic counterparts.
引用
- Worrell SG, Alvarado CE, Thibault D, et al. Impact of Diabetes on Pathologic Response to Multimodality Therapy for Esophageal Cancer. Ann Thorac Surg. 2022. PMID: 35970230. doi:10.1016/j.athoracsur.2022.07.046
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。